Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups.

ABSTRACT:

Background

Atopic dermatitis is highly prevalent in black/African American, Asian, and Hispanic patients, making assessment of these populations in clinical trials important. Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis. In two pivotal phase III clinical trials in patients aged ≥ 2 years, crisaborole was superior to vehicle in reducing global disease severity. The most common treatment-related adverse event was application site pain.

Objective

The objective of this study was to investigate the efficacy and safety of crisaborole according to patient race and ethnicity.

Methods

A pooled post hoc analysis by race and ethnicity of the two pivotal trials and a safety extension trial was pe

SUBMITTER: Callender VD 

PROVIDER: S-EPMC6764931 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature